Among the benign and intermediate lesions, enchondroma and osteochondroma showed a predominantly absent expression of PSMA (100% and 66.7%, respectively), while giant cell tumors of bone were most often positive, showing strong labelling (index 2) in 66.6% of cases. This evidence concerns the gene FOLH1 and giant cell tumor.